Human insulin/IGF-1 and familial longevity at middle age.

66Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

Abstract

Recently, we have shown that compared to controls, long-lived familial nonagenarians (mean age: 93.4 years) from the Leiden Longevity Study displayed a lower mortality rate, and their middle-aged offspring displayed a lower prevalence of cardio-metabolic diseases, including diabetes mellitus. The evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway has been implicated in longevity in model organisms, but its relevance for human longevity has generated much controversy. Here, we show that compared to their partners, the offspring of familial nonagenarians displayed similar non-fasted serum levels of IGF-1, IGFBP3 and insulin but lower non-fasted serum levels of glucose, indicating that familial longevity is associated with differences in insulin sensitivity.

Cite

CITATION STYLE

APA

Rozing, M. P., Westendorp, R. G. J., Frölich, M., de Craen, A. J. M., Beekman, M., Heijmans, B. T., … Leiden Longevity Study (LLS) Group. (2009). Human insulin/IGF-1 and familial longevity at middle age. Aging, 1(8), 714–722. https://doi.org/10.18632/aging.100071

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free